Disc Medicine, Inc.
IRONNext catalyst
DISC-0974
Myelofibrosis; Anemia
Get an email about IRON's next catalysts
Track Disc Medicine (IRON) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 3 past
DISC-0974 Phase 2 Est. Readout
Primary completion for DISC-0974 trial (NCT05320198) in Myelofibrosis; Anemia
SourceDISC-3405 Phase 2 Est. Readout
Estimated primary completion for DISC-3405 trial (NCT06985147) in Polycythemia Vera (PV). Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Myelofibrosis; Anemia
1 drug in this indication
Polycythemia Vera (PV)
1 drug in this indication
Erythropoietic Protoporphyria
1 drug in this indication
Erythropoietic Protoporphyria (EPP)
1 drug in this indication
Polycythemia vera
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Disc Medicine, Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Disc Medicine, Inc.'s (IRON) pipeline across Phase 3, Phase 2. Its lead program is DISC-1459 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Disc Medicine, Inc.'s next FDA catalyst?→
Disc Medicine, Inc.'s (IRON) next tracked catalyst is a Phase 2 readout expected May 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IRON biotech catalysts?→
Add IRON to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Disc Medicine, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.